News articles about Accelerate Diagnostics (NASDAQ:AXDX) have trended somewhat negative on Wednesday, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a daily sentiment score of -0.01 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.3720084830082 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s analysis:
- Accelerate Diagnostics (AXDX) Cut to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Accelerate Diagnostics Inc (AXDX) Expected to Post FY2017 Earnings of ($1.22) Per Share (americanbankingnews.com)
- Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey (americanbankingnews.com)
- Healthcare stock to Watch – Accelerate Diagnostics, Inc. (AXDX) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in … – GlobeNewswire (press release) (globenewswire.com)
Shares of Accelerate Diagnostics (AXDX) opened at $27.05 on Wednesday. The firm has a market cap of $1,515.12, a price-to-earnings ratio of -22.54 and a beta of 2.18. Accelerate Diagnostics has a 52 week low of $16.75 and a 52 week high of $30.45.
Several brokerages recently weighed in on AXDX. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday. BTIG Research cut shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $33.00.
In other news, Director Jack W. Schuler acquired 51,181 shares of the business’s stock in a transaction on Friday, November 10th. The stock was bought at an average price of $18.67 per share, for a total transaction of $955,549.27. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack W. Schuler acquired 50,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $18.46 per share, with a total value of $923,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 487,645 shares of company stock valued at $9,090,393. 50.00% of the stock is owned by company insiders.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.